Keyphrases
Israel
100%
Human Immunodeficiency Virus Type 1 (HIV-1)
44%
COVID-19
42%
BNT162b2 Vaccine
16%
SARS-CoV-2 Variants
14%
Virus
14%
HIV-1 Infection
13%
Direct-acting Antivirals
12%
Europe
12%
Hepatitis C Virus
12%
Israeli
12%
Resistance-associated Substitutions
11%
Geenius
11%
Hepatitis E Virus
10%
Immune Response
10%
Liver Transplant Recipients
10%
Men Who Have Sex with Men
10%
Vaccination
10%
HIV Infection
10%
HIV Patients
10%
Transmitted Drug Resistance mutations
9%
Viral Load
9%
Quantitative PCR
9%
Seroprevalence
9%
Genotype 1
9%
Antiretroviral Therapy
8%
Tel Aviv
8%
Drug Resistance
8%
Xpert
8%
Resistance mutations
8%
HIV Drug Resistance
8%
BNT162b2
8%
Receptor-binding Domain
8%
Virology
8%
IgG Antibody
7%
Circulating Recombinant Form
7%
Molecular Epidemiology
7%
CD4 Count
6%
SARS-CoV-2 Genome
6%
Fully Vaccinated
6%
Treatment Failure
6%
AIDS/HIV
6%
COVID-19 Pandemic
6%
Genotype 3
6%
Healthcare Workers
6%
Confidence Interval
6%
Epidemiology
6%
Variants of Concern
6%
Phylogenetic Analysis
6%
Unique Recombinant Forms
6%
Immunology and Microbiology
Human Immunodeficiency Virus 1
40%
Severe Acute Respiratory Syndrome Coronavirus 2
30%
Human Immunodeficiency Virus
23%
Vaccine Efficacy
20%
COVID-19
13%
Viral Load
11%
Seroprevalence
10%
Hepatitis B Virus
10%
Prevalence
9%
Hepatitis E Virus
8%
Spike
8%
Transplant Procedure
8%
Human Immunodeficiency Virus Infection
7%
Drug Resistance
7%
CD4 Lymphocyte Count
7%
Vaccination Policy
7%
Immune Response
7%
Viral Disease
6%
Next Generation Sequencing
6%
Molecular Epidemiology
6%
Lineages
6%
Immunoglobulin G Antibody
6%
Immunogenicity
6%
Neutralization
6%
Dynamics
6%
Hepatitis B Antigen
5%
HBsAg
5%
Hepatitis B
5%
Omicron Coronavirus Variant
5%
Real-Time Polymerase Chain Reaction
5%
Coronavirinae
5%
Immunoglobulin M
5%
Camel
5%
NS5A
5%
Phylogeny
5%
Medicine and Dentistry
Human Immunodeficiency Virus
44%
Severe Acute Respiratory Syndrome Coronavirus 2
39%
Infection
17%
Drug Resistance
13%
Hepatitis A Virus
10%
Prevalence
9%
COVID-19
9%
Men Who Have Sex with Men
8%
Neutralization
8%
Human Immunodeficiency Virus 1 Infection
8%
Antivirus Agent
8%
Cohort Effect
8%
Human Immunodeficiency Virus Infection
7%
Polymerase Chain Reaction
7%
Resistance Mutation
7%
Hepatitis C Virus
7%
Disease
6%
Antiretroviral Therapy
6%
Retrospective Cohort Study
6%
Coronavirinae
6%
Virus Infection
6%
Phylogeny
5%
Public Health
5%
Transitional Cell Carcinoma
5%
Acute Hepatitis
5%